The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ixazomib: First Global Approval
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Myeloma: From Front-Line to Relapsed Therapies
Moreau, P., & Touzeau, C. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e504 · Cited by 48
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
The versatility of boron in biological target engagement
Diaz, D. B., & Yudin, A. K. (2017) · Nature Chemistry · doi:10.1038/nchem.2814 · Cited by 331
Boronic acids as building blocks for the construction of therapeutically useful bioconjugates
António, J. P. M., Russo, R., Carvalho, C. P., Cal, P. M. S. D., & Gois, P. M. P. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00184k · Cited by 303
Design and discovery of boronic acid drugs
Plescia, J., & Moitessier, N. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112270 · Cited by 201
Metadata
- Authors
- Shirley, M.
- Venue
- Drugs
- Published
- 2016-02-04
- Volume
- 76
- Issue
- 3
- Pages
- 405-411
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2261920671
- Cited by
- 167
- References
- 1
- FWCI
- 11.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ixazomib: First Global Approval. https://app.cochat.ai/papers/10.1007/s40265-016-0548-5
- The paper
- Shirley, M. (2016). Ixazomib: First Global Approval. Drugs. https://doi.org/10.1007/s40265-016-0548-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.